#bharat biotech limited

[ujwala-hole11]

Human Rabies Vaccines Market Insights Market Expansion in Developing Regions

Rabies remains a serious global health concern, with fatal consequences if left untreated. The increasing focus on rabies prevention and vaccination programs has significantly impacted the human rabies vaccines market. As global awareness and government initiatives continue to rise, the demand for vaccines is growing, driving industry expansion and innovation.

Rising Global Demand and Awareness

The growing awareness about rabies prevention has resulted in increased demand for human rabies vaccines. Public health campaigns and educational programs, supported by organizations like the World Health Organization (WHO) and the Centers for Disease Control and Prevention (CDC), have played a crucial role in promoting vaccination.

The Role of WHO and Government Initiatives

Governments across the world are implementing national rabies elimination strategies. WHO’s "Zero by 30" initiative aims to eliminate human rabies deaths by 2030, driving investments in vaccine accessibility and distribution. Public vaccination programs are being expanded to reach underserved populations.

Innovations Driving Vaccine Development

Recent advancements in vaccine technology, including monoclonal antibody-based treatments and DNA vaccines, are transforming the human rabies vaccines market. Improved formulations with longer shelf life and enhanced immunogenicity are making vaccines more effective and accessible.

Challenges in Distribution and Access

Despite progress, distribution remains a significant challenge. Limited healthcare infrastructure, particularly in rural areas, makes vaccine accessibility difficult. Additionally, the requirement for cold chain storage increases logistical complexities, leading to supply shortages in certain regions.

Market Expansion in Developing Regions

Emerging economies in Asia, Africa, and Latin America are witnessing increased rabies vaccine demand due to higher exposure risks and improved healthcare investments. Efforts to expand healthcare infrastructure and government funding for vaccination programs are further boosting market growth.

Impact of Biotechnology on Vaccine Production

Biotechnology is playing a crucial role in enhancing vaccine production efficiency. The development of cell culture-based vaccines and recombinant DNA technology is reducing manufacturing costs while improving vaccine efficacy. These innovations are expected to drive market expansion in the coming years.

Pre-Exposure and Post-Exposure Prophylaxis Trends

The increasing adoption of pre-exposure prophylaxis (PrEP) among high-risk individuals, such as travelers and veterinarians, is boosting market demand. Post-exposure prophylaxis (PEP) remains the most critical treatment method, with advancements in vaccine regimens improving effectiveness and accessibility.

Competitive Landscape and Key Players

Major pharmaceutical companies, including Sanofi, GlaxoSmithKline, and Bharat Biotech, are actively investing in research and development. The competitive landscape is evolving as new players enter the market with innovative vaccine formulations and strategic partnerships to expand distribution networks.

Pricing and Affordability Factors

Cost remains a significant barrier to vaccine adoption in low-income countries. Government subsidies, non-governmental organization (NGO) interventions, and public-private collaborations are working to make rabies vaccines more affordable. Efforts to reduce production costs through technological advancements are also playing a role in improving affordability.

Future Outlook and Growth Prospects

The human rabies vaccines market is poised for steady growth, driven by increasing awareness, government support, and biotechnological advancements. The focus on eliminating rabies-related deaths through global initiatives is expected to create significant opportunities for market players. Strategic investments in innovation and accessibility will shape the future of the industry.

Conclusion

The human rabies vaccines market is experiencing strong growth, supported by government initiatives, global awareness programs, and advancements in vaccine technology. While challenges in distribution and affordability persist, ongoing research and strategic collaborations are expected to enhance vaccine accessibility and effectiveness. The market is set to witness continued expansion as efforts to eliminate rabies gain momentum.

[altiusinvestech]

Lord’s Mark Unlisted Shares: A Rising Star in Healthcare & Renewable Energy Investments?

Investing in unlisted shares offers a unique opportunity to participate in a company's growth before it enters the public market. One such company attracting investor attention is Lord's Mark Industries Limited, a diversified conglomerate with significant ventures in the healthcare and renewable energy sectors. This article provides an in-depth analysis of Lord's Mark Industries' unlisted shares, evaluating their potential as a promising investment.

Company Overview

Established in 1998 in Mumbai, Lord's Mark Industries began its journey in the paper manufacturing sector under the brand name "SAPPHIRE." Over the past 25 years, the company has expanded its operations into various sectors, including:

Diagnostic and MedTech: Focusing on medical diagnostics and technology-driven healthcare solutions.

LED-Solar: Engaging in the production of LED lighting and solar energy solutions.

Paper Manufacturing: Continuing its legacy in the paper industry.

Additionally, Lord's Mark has diversified investments in sectors such as electric vehicles, biotechnology, and insurance through its sister companies, including Lords Automotive and Lords Mark Biotech.

Financial Performance and Share Details

As of March 31, 2024, Lord's Mark Industries has 56,582,108 outstanding shares, each with a face value of Rs 5. The company's authorized and paid-up share capital stands at Rs 4 crore. The unlisted shares are available for trading, with a lot size of 100 shares.

The company's financial metrics include a market capitalization of Rs 2,887 crore, a price-to-earnings (P/E) ratio of 253.97, and a price-to-book (P/B) ratio of 30.77. The debt-to-equity ratio is 2.43, indicating a moderate level of debt relative to equity. The return on equity (ROE) stands at 12.73%, reflecting the company's profitability in generating returns on shareholders' investments.

Strategic Initiatives in Renewable Energy

Lord's Mark Industries has made significant strides in the renewable energy sector. In January 2025, the company secured a 300 MW solar contract under the Uttar Pradesh New and Renewable Energy Development Agency or ‘UPNEDA’ program. This project, awarded at a competitive rate of Rs 4.80 per unit, involves installing solar panels on government building rooftops, aligning with India's sustainable energy goals.

This achievement underscores the company's commitment to advancing India's green energy transition and showcases its capability to undertake large-scale renewable energy projects.

Recognition and Future Prospects

The company's efforts have not gone unnoticed. In January 2025, Lord's Mark Industries was honored with the Nava Bharat CSR Award 2025 for its contributions to healthcare. This accolade reflects the company's dedication to corporate social responsibility and its impact on the healthcare sector.

Looking ahead, Lord's Mark Industries has expressed intentions to go public. In 2024, the company announced plans to raise Rs 500 crore through an Initial Public Offering (IPO) in the first half of the year. While the current status of the IPO requires verification, such a move could enhance liquidity for investors and provide capital for further expansion.

Investment Considerations

Investing in unlisted shares like those of Lord's Mark Industries offers several potential benefits-

High Growth Potential: Early investment in a diversified and expanding company can lead to substantial returns, especially if the company goes public.

Portfolio Diversification: Unlisted shares can add diversity to an investment portfolio, potentially reducing overall risk.

Access to Pre-IPO Opportunities: Investors can acquire shares at potentially lower prices before the company enters the public market.

However, potential investors should also consider the associated risks-

Liquidity Constraints: Unlisted shares are not traded on public exchanges, making it more challenging to sell them quickly.

Valuation Uncertainty: Determining the fair market value of unlisted shares can be complex due to the lack of transparent pricing mechanisms.

Regulatory and Market Risks: Changes in regulations or market conditions can impact the company's performance and, consequently, the value of its shares.

If You Want To Buy Lord Mark Industries Unlisted Shares. You can buy from Altius Investech!.

Final Thoughts

Lord's Mark Industries Limited presents a compelling case for investment in its unlisted shares, given its diversified operations, strategic initiatives in high-growth sectors like healthcare and renewable energy, and recognition for its corporate social responsibility efforts. While the potential for significant returns exists, especially with the prospect of an IPO, investors must conduct thorough due diligence and assess their risk tolerance before investing. Engaging with financial advisors and staying informed about the company's developments are prudent steps to make informed investment decisions.

You Can Also Read Our Other Blogs

Lord’s Mark Industries: Share Price, IPO Plans, Recent News & Financial Highlights

[news365timesindia]

[ad_1] Lords Mark Industries Limited, a distinguished company known for its diverse portfolio, has been awarded the prestigious NavaBharat CSR Award 2025 in the Healthcare category. The grand ceremony took place at ITC Grand Central, Mumbai, where industry leaders and achievers were recognized for their exceptional contributions to Corporate Social Responsibility (CSR).   Lords Mark Industries Limited Honoured at NavaBharat CSR Summit & Awards 2025   Mr. Sachidanand Upadhyay, Managing Director, Lords Mark Industries, was recognized as a CSR Hero for his outstanding efforts in driving impactful healthcare initiatives. On his behalf, Mr. Vinay Sarda, Director, Lords Mark Industries Ltd., received the award from Shri C.P. Radhakrishnan, Hon’ble Governor of Maharashtra. The award is a testament to Lords Mark Industries' unwavering commitment to social welfare, particularly in the healthcare sector. Through its various CSR initiatives, the company has exemplified the true spirit of philanthropy, inspiring change, and fostering progress toward building a New India. Expressing his gratitude, Mr. Sachidanand Upadhyay, Managing Director, Lords Mark Industries said, "At Lords Mark Industries, we believe that access to quality healthcare is a fundamental right. This recognition reinforces our commitment to driving meaningful change through sustainable and impactful healthcare initiatives. As we work towards a Viksit Bharat, we remain dedicated to empowering communities and fostering a healthier and stronger India." Lord’s Mark Industries operates through key subsidiaries, including LordsMed, Lord’s Mark Insurance Broking Limited, Lord’s Mark Biotech, Lords Mark Microbiotech, and Lords Automative Private Limited, along with verticals in renewable energy products and paper. Committed to innovation and excellence, the company continues to expand while upholding the highest quality standards. Diversification remains the foundation of Lord’s Mark Industries' sustained growth and success. About Lord’s Mark Industries Ltd Incorporated in 1998, Lord’s Mark Industries Private Ltd. (Lord’s) has made impressive growth starting from paper to LED to Renewable energy and making grand in the medical diagnostic industry. Lord’s and its subsidiaries have made a mark in Electric Vehicle, Genome Testing, Pharma and Healthcare. Growth through diversification has become the trend setter and has been the cornerstone of success at Lord’s.   Website lordsmark.com. !function(f,b,e,v,n,t,s) if(f.fbq)return;n=f.fbq=function()n.callMethod? n.callMethod.apply(n,arguments):n.queue.push(arguments); if(!f._fbq)f._fbq=n;n.push=n;n.loaded=!0;n.version='2.0'; n.queue=[];t=b.createElement(e);t.async=!0; t.src=v;s=b.getElementsByTagName(e)[0]; s.parentNode.insertBefore(t,s)(window,document,'script', 'https://connect.facebook.net/en_US/fbevents.js'); fbq('init', '311356416665414'); fbq('track', 'PageView'); [ad_2] Source link

[news365times]

[ad_1] Lords Mark Industries Limited, a distinguished company known for its diverse portfolio, has been awarded the prestigious NavaBharat CSR Award 2025 in the Healthcare category. The grand ceremony took place at ITC Grand Central, Mumbai, where industry leaders and achievers were recognized for their exceptional contributions to Corporate Social Responsibility (CSR).   Lords Mark Industries Limited Honoured at NavaBharat CSR Summit & Awards 2025   Mr. Sachidanand Upadhyay, Managing Director, Lords Mark Industries, was recognized as a CSR Hero for his outstanding efforts in driving impactful healthcare initiatives. On his behalf, Mr. Vinay Sarda, Director, Lords Mark Industries Ltd., received the award from Shri C.P. Radhakrishnan, Hon’ble Governor of Maharashtra. The award is a testament to Lords Mark Industries' unwavering commitment to social welfare, particularly in the healthcare sector. Through its various CSR initiatives, the company has exemplified the true spirit of philanthropy, inspiring change, and fostering progress toward building a New India. Expressing his gratitude, Mr. Sachidanand Upadhyay, Managing Director, Lords Mark Industries said, "At Lords Mark Industries, we believe that access to quality healthcare is a fundamental right. This recognition reinforces our commitment to driving meaningful change through sustainable and impactful healthcare initiatives. As we work towards a Viksit Bharat, we remain dedicated to empowering communities and fostering a healthier and stronger India." Lord’s Mark Industries operates through key subsidiaries, including LordsMed, Lord’s Mark Insurance Broking Limited, Lord’s Mark Biotech, Lords Mark Microbiotech, and Lords Automative Private Limited, along with verticals in renewable energy products and paper. Committed to innovation and excellence, the company continues to expand while upholding the highest quality standards. Diversification remains the foundation of Lord’s Mark Industries' sustained growth and success. About Lord’s Mark Industries Ltd Incorporated in 1998, Lord’s Mark Industries Private Ltd. (Lord’s) has made impressive growth starting from paper to LED to Renewable energy and making grand in the medical diagnostic industry. Lord’s and its subsidiaries have made a mark in Electric Vehicle, Genome Testing, Pharma and Healthcare. Growth through diversification has become the trend setter and has been the cornerstone of success at Lord’s.   Website lordsmark.com. !function(f,b,e,v,n,t,s) if(f.fbq)return;n=f.fbq=function()n.callMethod? n.callMethod.apply(n,arguments):n.queue.push(arguments); if(!f._fbq)f._fbq=n;n.push=n;n.loaded=!0;n.version='2.0'; n.queue=[];t=b.createElement(e);t.async=!0; t.src=v;s=b.getElementsByTagName(e)[0]; s.parentNode.insertBefore(t,s)(window,document,'script', 'https://connect.facebook.net/en_US/fbevents.js'); fbq('init', '311356416665414'); fbq('track', 'PageView'); [ad_2] Source link

[indianbiogas]

Biogas in Kerala: Advancements and Opportunities

Kerala, known for its progressive approach to sustainable development, has been actively integrating biogas technology to address waste management challenges and promote renewable energy. The state’s commitment to environmental conservation is evident through various initiatives and projects aimed at harnessing the potential of biogas.

1. Government Initiatives and Policies

The Kerala State Human Rights Commission has mandated the inclusion of biogas plants in flat construction permits, ensuring that new residential complexes incorporate sustainable waste management solutions. This policy aims to address waste disposal issues and promote renewable energy sources.

2. Large-Scale Biogas Plants

The Agency for New and Renewable Energy Research and Technology (ANERT) has been instrumental in promoting biogas solutions across Kerala. They have installed over 100 large biogas plants in medical colleges, district hospitals, and private institutions, with capacities ranging from 15 to 70 cubic meters. Collectively, these plants generate approximately 10 lakh cubic meters of biogas annually, utilized for thermal applications and electricity generation.

3. Compressed Biogas (CBG) Plants

In a significant development, Bharat Petroleum Corporation Limited (BPCL) is setting up a compressed biogas plant at Brahmapuram in Kochi. The plant is designed to process 150 metric tonnes of organic waste daily, converting it into compressed biogas. The project aims to mitigate pollution and manage waste effectively in the region. Construction commenced in March 2024, with operations expected to begin by February 2025.

4. Eco-Friendly Toilets and Waste Management

Biotech India has developed eco-friendly toilets that convert human excreta into biogas, providing a sustainable solution to waste management and energy needs. These toilets are particularly beneficial in areas with limited access to sanitation facilities, contributing to improved hygiene and renewable energy production.

5. Integrated Rural Technology Centre (IRTC)

Established in 1987, the Integrated Rural Technology Centre (IRTC) in Palakkad has been at the forefront of rural innovation, including biogas technology. IRTC has contributed to the development of smokeless chulhas, small hydel projects, and portable domestic biogas plants, enhancing the standard of living in rural areas.

6. Biogas Plant Manufacturers in Kerala

Several companies biogas in Kerala specialize in the manufacturing and installation of biogas plants. For instance, Sewaf Energy India Private Limited offers customized biogas solutions in Kochi, Kozhikode, and Thrissur, catering to both domestic and commercial needs.

7. National Biogas Development Project

The National Biogas Development Project, under the Department of Agriculture Development and Farmers’ Welfare, provides assistance for setting up biogas plants, including those linked to sanitary toilets. The project aims to promote the adoption of biogas technology among farmers and rural households.

Conclusion

Kerala’s proactive approach to integrating biogas technology reflects its dedication to sustainable development and environmental conservation. Through government policies, large-scale projects, and community initiatives, the state is effectively harnessing the potential of biogas to address waste management challenges and promote renewable energy.

[pharmawalksjobs]

Bharat Biotech - Walk-in for Production/ Engineering departments on 25th Jan 2025

Greetings from Bharat Biotech International Limited! We are conducting various roles in Production & Engineering departments on 25th January 2025 @ Hyderabad. Walk-in interview details Date of interview: 25th January 2025 Time: 10.00 AM – 2.00 PM Venue: Bharat Biotech International Limited, Genome Valley, Turkapally, Shamirpet, Hyderabad – 500078. Contact – HR Team (9014552718). We are hiring for…

[businessitblog]

product based companies in Hyderabad

Hyderabad, often referred to as the "City of Pearls," has swiftly emerged as a prominent center for information technology, pharmaceuticals, and manufacturing industries. With its dynamic business environment and strategic location, the city has become a preferred destination for product-based companies, fostering innovation, creating jobs, and significantly boosting the local and national economy.

This comprehensive exploration delves into the significance, challenges, and future potential of product-based companies in Hyderabad.

What Are Product-Based Firms in Hyderabad?

Product-based companies focus on creating, manufacturing, and selling tangible goods, ranging from software solutions and industrial machinery to everyday consumer products. Unlike service-based firms that deliver intangible services like consulting or customer support, these companies offer products that users can physically interact with.

Examples Include:

Consumer electronics

Pharmaceutical drugs

Automobile components

In Hyderabad, product-based companies span diverse sectors, each playing a crucial role in the city's industrial landscape and growth.

Why Hyderabad is Ideal for Product-Based Companies

1. Thriving Tech and Industrial EcosystemThe city hosts numerous industrial parks and Special Economic Zones (SEZs) that foster business growth. Multinational corporations like Microsoft, Amazon, and Google have established a strong presence, driving innovation and market expansion.

2. Skilled Workforce AvailabilityHyderabad boasts prestigious educational institutions such as the Indian School of Business (ISB) and the International Institute of Information Technology (IIIT), ensuring access to a pool of highly talented professionals.

3. Supportive Government PoliciesThe Telangana government promotes business growth through initiatives like TS-iPASS, simplifying industrial clearances and encouraging the establishment of product-based companies.

4. Strong Connectivity and InfrastructureWith the Rajiv Gandhi International Airport, comprehensive road networks, and rail links, Hyderabad ensures seamless logistics operations for product-focused enterprises.

Prominent Product-Based Companies in Hyderabad

Tech and IT Products:

Microsoft India Development Center: A key player in software innovation

Amazon Web Services (AWS): Leading provider of cloud-based solutions

Pharmaceutical and Biotech Products

Dr. Reddy's Laboratories: A global leader in pharmaceutical manufacturing.

Aurobindo Pharma: Renowned for its extensive range of generic drugs.

Automobile Components

Bharat Forge: Specializes in automotive parts forging.

ZF Group: A leader in driveline and chassis technology.

Consumer Goods

Procter & Gamble (P&G): Manufactures household goods.

ITC Limited: Offers packaged foods, personal care products, and more.

Key Benefits of Hyderabad's Product-Based Companies

Access to Talent and Innovation Hubs

Strong industry-academia collaborations fuel innovation.

A rich pool of engineers, researchers, and product designers.

Collaborative Environment

Numerous innovation hubs and R&D centres foster product development.

Export Market Expansion

Strategic location and superior connectivity facilitate access to both domestic and international markets.

Challenges Facing Product-Based Companies in Hyderabad

High Competition

The growing number of companies across various sectors intensifies market competition.

Logistics and Supply Chain Issues

Despite robust infrastructure, occasional delays in material sourcing and customs clearance can occur.

Talent Retention

The competitive job market makes retaining top talent a persistent challenge.

Emerging Sectors and Future Trends

IoT and Smart Devices

The demand for IoT products continues to rise, positioning Hyderabad as a key player.

Renewable Energy Products

Companies involved in manufacturing solar panels, wind energy components, and energy-efficient appliances are expanding rapidly.

Biotech and Healthcare Innovations

The sector is experiencing significant growth due to advancements in healthcare technology.

Steps to Start a Product-Based Company in Hyderabad

Market Research and Planning

Analyze market demand and assess the competitive landscape.

Develop a comprehensive business plan.

Legal Considerations

Register the company and obtain the necessary licenses.

Ensure compliance with safety and quality regulations.

Location Selection

Choose strategic locations near suppliers, customers, and logistics hubs.

Financing and Infrastructure

Explore funding options such as venture capital, government grants, or business loans.

Marketing and Distribution

Develop a robust marketing strategy.

Establish an efficient distribution network.

Conclusion

With its robust infrastructure, skilled workforce, and favorable business environment, Hyderabad presents a fertile ground for product-based companies. From technology and pharmaceuticals to consumer goods and automotive components, the city offers vast opportunities for entrepreneurs and established enterprises alike.

FAQs

What are the key sectors for product-based companies in Hyderabad? Key sectors include technology, pharmaceuticals, automobile components, and consumer goods.

How can I start a product-based company in Hyderabad? Begin with thorough market research, business registration, securing funds, and establishing a distribution network.

What challenges do product-based companies face in Hyderabad? Intense competition, logistics issues, and talent retention are common challenges.

Explore for more: MarketingHack4U - Marketing and Tech Blog

Best news portal development company in India

Best news portal development company in India

[biotichealthcare]

The report published by Kearney in collaboration with the Confederation of Indian Industry titled “Taking India’s life sciences industry to the global stage”, reported that “India’s vaccines industry can grow from $2 billion to $4 billion or even $5 billion”. This has been made possible by a number of factors prominent being the inclusion of vaccines in the product portfolios of several domestic and global pharmaceutical companies. With the pandemic kicking in 2019 end, the entire world came together to build an effective vaccine to fight against the deadly coronavirus.

This report speaks a lot about the Indian biosimilars and vaccines industries and how it is competing globally and scopes for India in the global biosimilars and vaccines industry. It lays down the challenges faced by the Indian pharmaceutical industry and how we can overcome these. It lays down abundant solutions to the challenges faced and how India can ace the Global Pharma sector and command its worthy position both in terms of volume and value.

Indian Vaccine Industry 

The global Pharmaceutical industry has made vaccines their priority. India commands a massive 40% share of the global vaccine industry by volume. India has been playing a pivotal role in combating deadly diseases for years and now the coronavirus pandemic. India is all set to grow to hold a more significant place in the global pharma industry in the coming years. With the introduction of newer and better technologies such as gene therapies, Ai-based informatics, etc has opened boundless opportunities to conduct research and experimentation and develop innovative and effective medications.

India already possesses a strong local pharma industry, fundamentally strong technical capabilities, and rich scientific acumen, that has helped us emerge as an innovational hub of the world. India is the global supplier of drugs and medicines and everybody prefers India for its low-cost manufacturing processes and affordable drugs.

However, Indian Pharmaceutical Industry still lags behind in terms of the value of our market share through being the third-largest volume producer. India faces several challenges that need to be overcome. COVID pandemic offers a great opportunity for India to take a step ahead to bag the top position both in terms of volume and value.

Massive Scope for Global Vaccine supply

There is abundant scope for the export of COVID-19 vaccines globally to countries unable to manufacture vaccines on their own. Moreover, there are several diseases globally that need vaccination, and these infectious diseases amount to more than 70% of the world population. Many countries rely on India for the supply of vaccine doses to combat various infectious diseases. Our own nation has a huge demand for vaccines owing to the huge population count and prevalence of abundant diseases such as diphtheria, tetanus, hepatitis B, measles, mumps, rubella, etc.

India has long been involved in supplying the highly required vaccines to several developing nations at the most affordable prices. So now also the world relied on India for COVID vaccine and India proved to be the biggest exporter of Covid vaccines globally. India itself faced a shortage of vaccines initially due to the heavy burden on the limited resources besides having huge commitments globally. Only two vaccine manufacturers i.e. Serum Institute of India (SII) and Bharat Biotech were operational in the beginning. With limited manufacturing resources, it became difficult to meet both domestic and global vaccine requirements.

This shows the scope for vaccine manufacturing in India provided we develop the required infrastructure and support our pharma medicine developers with the latest and advanced technologies to conduct their research. India requires a favorable statutory and political environment to lead the world with its pharmaceutical products. To be the global leader in terms of value, India needs to be more research-oriented to develop unique formulations to treat health conditions and obtaining Intellectual Property Rights. This is how India can occupy a major pharma share both in terms of volume as well as value.

[ranakaushal]

10th Annual Biotech Industry Conclave on Biotechnology for Humanity: Innovations Shaping a Better World

KIIT School of Biotechnology organized the 10th Biotech Industrial Conclave on “Biotechnology for Humanity: Innovations Shaping a Better World” during 23rd–24thAugust 2024. The conclave, spanning over two days, had enlightening talks, discussion and spirited interactions between experts from the biotech industry, academia, and students to foster collaboration and innovation in the field. During the inaugural session, Dr. Achyuta Samanta, Founder, KIIT & KISS, welcomed all the dignitaries and stressed upon development of strong collaboration between KIIT and biotechnology industry.

Padmashri Dr. Krishna Ella, Founder & Executive Chairman, Bharat Biotech International Limited echoed the need for close interaction between premier educational institutes and the biotech industry for inclusive growth. Dr. Ella, in his keynote address, shared his personal journey in entrepreneurship and innovation, highlighting the challenges and rewards of building a successful biotech company. He emphasized the importance of practical learning experiences for PhD students and the role of the Ella Foundation in supporting their entrepreneurial endeavors. He also stressed upon the need for vaccine development for neglected diseases.

Dr. Shilpa Gadgil, Vice President, Enzene Biosciences Ltd.; Dr. Priyabrata Pattnaik, Dy. Managing Director, Indian Immunologicals Ltd.; Raghavendra P. Rao, Principal Scientist, The Himalaya Drug Company; Dr. Ranendra N. Saha, Chief Scientific Advisor, Biophore; Dr. Sreedharala Venkata Nookaraju, Executive Vice President, Aizant Drug Research Soln. Lt;. and Dr. Prabuddha Kundu, Co-Founder & MD, Premas Biotech discussed about emerging trends in complex therapeutic biomolecules like monoclonal antibodies, novel vaccines, complex protein production processes. Mr. Dushyant Deshmukh, GM-HR, Glenmark Pharmaceuticals; Mr. Hemant Nikam, Sr Director and Head HR, Eisai Pharmaceuticals India; and Mr. Pritesh Bhatia, Associate Director HR, Jubilant Biosys Ltd. discussed about the emerging trends in human resource requirements and how students should prepare themselves to become successful biotechnology professionals.

Mr. Lalit Sisaudia, Vice President of Nutaste Group and Ms. Rosina Panda, Business Manager, Intertek spoke about food safety and the need for precision to address global food security challenges.

Dr. Emili Banerjee, Senior Genetic Counselor, Neuberg Diagnostics, Dr. Raghavendra Goud, Executive Director at PharmNXT Biotech and Mr. Ashish Dubey, Co-Founder and COO, Redcliffe Labs discussed the opportunities in molecular diagnostics in healthcare and how AI driven processes can accelerate disease detection and make healthcare accessible in the remote regions of the country. In the last session, five alumni turned entrepreneurs Mr. Pritam Dhalla, Founder, Larkai Healthcare; Mr. Akashdeep Dan, Co-Founder of Bogmalo Foods and Hospitality; Mr. Prateek Mahapatra, Director of Grow Green Consortium Pvt. Ltd.; Ms. Varsha Biswal, CEO, Trupti Dairy; and Dr. Shailesh Samal, CEO, Inflanova AB shared the memories in KSBT and how it helped them to excel in their areas of passion.

Dr. Mrutyunjay Suar, DG-Research & Innovation, and CEO, KIIT-TBI discussed about start-up innovation system in KIIT and role of Bhubaneswar City Knowledge Cluster in developing fruitful collaboration in the biotechnology sector. Dr. Jnyana Ranjan Mohanty, Registrar and Dr. Srinivas Patnaik, Dean KSBT described the academic initiatives taken for skill development of the students. Dr. Rahul Modak, Convener of the conclave thanked all the dignitaries and participants for their active participation and contribution in the conclave.

[digimarketresearch]

Chikungunya Treatment Market Size, Share, Trends, Growth and Competitive Outlook

"Global Chikungunya treatment Market study by Data Bridge Market Research provides details about the market dynamics affecting the Chikungunya treatment market, Market scope, Market segmentation and overlays shadow upon the leading market players highlighting the favourable competitive landscape and trends prevailing over the years.

An all-inclusive Chikungunya treatment market report enables clients to boost revenues from new and existing customer base as well as identify key trends and hidden opportunities, latest developments, market shares, and strategies that are employed by the major market players. Client or business can get aware of the impact of opportunities that are offered by the market and hence design sustainable and competitive strategies in times of rapid development. A range of definitions and classification of the Chikungunya treatment industry, applications of the Chikungunya treatment industry and chain structure are given in the credible Chikungunya treatment report.

Chikungunya treatment business document is also helpful to understand the regional analysis of the market and paradigm shift in consumer preferences. This report makes it easy to analyze various market perspectives with the help of Porter’s five forces analysis. The company profiles of all the top market players and brands with moves like product launches, joint ventures, mergers and acquisitions which in turn is affecting the sales, import, export, revenue and CAGR values are revealed in this market report. Key market dynamics of the Chikungunya treatment industry is the best part about Chikungunya treatment market research report.

Access Full 350 Pages PDF Report @

Data Bridge Market Research analyses that the chikungunya treatment will exhibit a CAGR of around 7.40% for the forecast period of 2021-2028. Rising prevalence of dengue in tropical and sub-tropical regions, increased government initiatives and funding to fight against dengue, surge in the research and development activities for the development of novel drugs and therapies and increased expenditure for the development of healthcare infrastructure are the major factors attributable to the growth of chikungunya treatment market.

Highlights of TOC:

Chapter 1: Market overview

Chapter 2: Global Chikungunya treatment Market

Chapter 3: Regional analysis of the Global Chikungunya treatment Market industry

Chapter 4: Chikungunya treatment Market segmentation based on types and applications

Chapter 5: Revenue analysis based on types and applications

Chapter 6: Market share

Chapter 7: Competitive Landscape

Chapter 8: Drivers, Restraints, Challenges, and Opportunities

Chapter 9: Gross Margin and Price Analysis

Countries Studied:

North America (Argentina, Brazil, Canada, Chile, Colombia, Mexico, Peru, United States, Rest of Americas)

Europe (Austria, Belgium, Denmark, Finland, France, Germany, Italy, Netherlands, Norway, Poland, Russia, Spain, Sweden, Switzerland, United Kingdom, Rest of Europe)

Middle-East and Africa (Egypt, Israel, Qatar, Saudi Arabia, South Africa, United Arab Emirates, Rest of MEA)

Asia-Pacific (Australia, Bangladesh, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Sri Lanka, Thailand, Taiwan, Rest of Asia-Pacific)

The major players covered in the chikungunya treatment market report are Merck KGaA, QIAGEN, Bio-Rad Laboratories, Danaher., Hologic, Inc., BD, Abbott, Thermo Fisher Scientific, Inc., F. Hoffmann-La Roche Ltd, Siemens Healthcare GmbH, bioMérieux SA, Zydus Cadila, Teva Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited., Themis Bioscience GmbH, Bharat Biotech., Paradigm Biopharmaceuticals Ltd, Nano Therapeutics Pvt Ltd, Hawaii Biotech Inc. and Integral Molecular among other domestic and global players. Market share data is available for Global, North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South America separately. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.

Browse Trending Reports:

Alzheimers Disease Diagnostic Market

Europe Hearing Aids Market

Smart Health Watches Market

Europe Hospital Furniture Market

Middle East And Africa Foot And Ankle Devices Market

About Data Bridge Market Research:

Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Contact Us:

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

Email: corporatesales@databridgemarketresearch.com"

[ramtracking]

Clinical trials of first adult TB vaccine derived from human source begins [ BCG vaccine ]

Clinical trials of first adult TB vaccine derived from human source begins [News Summary] Bharat Biotech International Limited, in collaboration with Biofabri, has started a series of clinical trials in adults in the country to… India News: HYDERABAD: Bharat Biotech, based in Hyderabad, has started clinical trials of MTBVAC, the world’s first Mycobacterium… World Tuberculosis (TB) Day is marked…

[aimarketresearch]

Chikungunya Treatment Market Size, Share, Trends, Demand, Growth and Competitive Outlook

Global Chikungunya treatment Market study by Data Bridge Market Research provides details about the market dynamics affecting the Chikungunya treatment market, Market scope, Market segmentation and overlays shadow upon the leading market players highlighting the favourable competitive landscape and trends prevailing over the years.

An all-inclusive Chikungunya treatment market report enables clients to boost revenues from new and existing customer base as well as identify key trends and hidden opportunities, latest developments, market shares, and strategies that are employed by the major market players. Client or business can get aware of the impact of opportunities that are offered by the market and hence design sustainable and competitive strategies in times of rapid development. A range of definitions and classification of the Chikungunya treatment industry, applications of the Chikungunya treatment industry and chain structure are given in the credible Chikungunya treatment report.

Chikungunya treatment business document is also helpful to understand the regional analysis of the market and paradigm shift in consumer preferences. This report makes it easy to analyze various market perspectives with the help of Porter’s five forces analysis. The company profiles of all the top market players and brands with moves like product launches, joint ventures, mergers and acquisitions which in turn is affecting the sales, import, export, revenue and CAGR values are revealed in this market report. Key market dynamics of the Chikungunya treatment industry is the best part about Chikungunya treatment market research report.

Data Bridge Market Research analyses that the chikungunya treatment will exhibit a CAGR of around 7.40% for the forecast period of 2021-2028. Rising prevalence of dengue in tropical and sub-tropical regions, increased government initiatives and funding to fight against dengue, surge in the research and development activities for the development of novel drugs and therapies and increased expenditure for the development of healthcare infrastructure are the major factors attributable to the growth of chikungunya treatment market.

Access Full 350 Pages PDF Report @

Highlights of TOC:

Chapter 1: Market overview

Chapter 2: Global Chikungunya treatment Market

Chapter 3: Regional analysis of the Global Chikungunya treatment Market industry

Chapter 4: Chikungunya treatment Market segmentation based on types and applications

Chapter 5: Revenue analysis based on types and applications

Chapter 6: Market share

Chapter 7: Competitive Landscape

Chapter 8: Drivers, Restraints, Challenges, and Opportunities

Chapter 9: Gross Margin and Price Analysis

Countries Studied:

North America (Argentina, Brazil, Canada, Chile, Colombia, Mexico, Peru, United States, Rest of Americas)

Europe (Austria, Belgium, Denmark, Finland, France, Germany, Italy, Netherlands, Norway, Poland, Russia, Spain, Sweden, Switzerland, United Kingdom, Rest of Europe)

Middle-East and Africa (Egypt, Israel, Qatar, Saudi Arabia, South Africa, United Arab Emirates, Rest of MEA)

Asia-Pacific (Australia, Bangladesh, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Sri Lanka, Thailand, Taiwan, Rest of Asia-Pacific)

The major players covered in the chikungunya treatment market report are Merck KGaA, QIAGEN, Bio-Rad Laboratories, Danaher., Hologic, Inc., BD, Abbott, Thermo Fisher Scientific, Inc., F. Hoffmann-La Roche Ltd, Siemens Healthcare GmbH, bioMérieux SA, Zydus Cadila, Teva Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited., Themis Bioscience GmbH, Bharat Biotech., Paradigm Biopharmaceuticals Ltd, Nano Therapeutics Pvt Ltd, Hawaii Biotech Inc. and Integral Molecular among other domestic and global players. Market share data is available for Global, North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South America separately. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.

Browse Trending Reports:

Respiratory Polygraphs Market

Biomedical Refrigerators And Freezers Market

Digital Mobile X Ray Devices Market

Point Of Care Poc Urinalysis Market

Viral Clearance Services Market

About Data Bridge Market Research:

Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Contact Us:

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

Email: corporatesales@databridgemarketresearch.com

[indianbiogas]

Biogas in Kerala: Advancements and Opportunities

Kerala, known for its progressive approach to sustainable development, has been actively integrating biogas technology to address waste management challenges and promote renewable energy. The state’s commitment to environmental conservation is evident through various initiatives and projects aimed at harnessing the potential of biogas.

1. Government Initiatives and Policies

The Kerala State Human Rights Commission has mandated the inclusion of biogas plants in flat construction permits, ensuring that new residential complexes incorporate sustainable waste management solutions. This policy aims to address waste disposal issues and promote renewable energy sources.

2. Large-Scale Biogas Plants

The Agency for New and Renewable Energy Research and Technology (ANERT) has been instrumental in promoting biogas solutions across Kerala. They have installed over 100 large biogas plants in medical colleges, district hospitals, and private institutions, with capacities ranging from 15 to 70 cubic meters. Collectively, these plants generate approximately 10 lakh cubic meters of biogas annually, utilized for thermal applications and electricity generation.

3. Compressed Biogas (CBG) Plants

In a significant development, Bharat Petroleum Corporation Limited (BPCL) is setting up a compressed biogas plant at Brahmapuram in Kochi. The plant is designed to process 150 metric tonnes of organic waste daily, converting it into compressed biogas. The project aims to mitigate pollution and manage waste effectively in the region. Construction commenced in March 2024, with operations expected to begin by February 2025.

4. Eco-Friendly Toilets and Waste Management

Biotech India has developed eco-friendly toilets that convert human excreta into biogas, providing a sustainable solution to waste management and energy needs. These toilets are particularly beneficial in areas with limited access to sanitation facilities, contributing to improved hygiene and renewable energy production.

5. Integrated Rural Technology Centre (IRTC)

Established in 1987, the Integrated Rural Technology Centre (IRTC) in Palakkad has been at the forefront of rural innovation, including biogas technology. IRTC has contributed to the development of smokeless chulhas, small hydel projects, and portable domestic biogas plants, enhancing the standard of living in rural areas.

6. Biogas Plant Manufacturers in Kerala

Several companies biogas in Kerala specialize in the manufacturing and installation of biogas plants. For instance, Sewaf Energy India Private Limited offers customized biogas solutions in Kochi, Kozhikode, and Thrissur, catering to both domestic and commercial needs.

7. National Biogas Development Project

The National Biogas Development Project, under the Department of Agriculture Development and Farmers’ Welfare, provides assistance for setting up biogas plants, including those linked to sanitary toilets. The project aims to promote the adoption of biogas technology among farmers and rural households.

Conclusion

Kerala’s proactive approach to integrating biogas technology reflects its dedication to sustainable development and environmental conservation. Through government policies, large-scale projects, and community initiatives, the state is effectively harnessing the potential of biogas to address waste management challenges and promote renewable energy.

[pharmawalksjobs]

Job opportunity for Production department at Bharat biotech

Bharat Biotech International Limited is a versatile biotechnology firm that focuses on research, development, and production of vaccines and biotherapeutics. The company is dedicated to creating advanced vaccines and bio-therapeutics through groundbreaking and cooperative research efforts. BBIL’s cutting-edge manufacturing facility stands as the largest in the Asia-Pacific region. Join Bharat…

[themarketinsights]

Vaccine Conjugate Market is set for a Potential Growth Worldwide: Excellent Technology Trends with Business Analysis

Latest released the research study on Global Vaccine Conjugate Market, offers a detailed overview of the factors influencing the global business scope. Vaccine Conjugate Market research report shows the latest market insights, current situation analysis with upcoming trends and breakdown of the products and services. The report provides key statistics on the market status, size, share, growth factors of the Vaccine Conjugate The study covers emerging player’s data, including: competitive landscape, sales, revenue and global market share of top manufacturers are Bharat Biotech (India), Biological E (India), CSL Limited (Australia), GlaxoSmithKline, plc. (U.K.), Merck and Company (U.S.), Neuron Biotech (U.S.), Novartis AG (Switzerland), Pfizer, Inc. (U.S.), Sanofi Pasteur (France), Serum Institute of India (India)

Free Sample Report + All Related Graphs & Charts @: https://www.advancemarketanalytics.com/sample-report/3382-global-vaccine-conjugate-market-1?utm_source=Organic&utm_medium=Vinay

Conjugate vaccines refer to those vaccines that contain bacterial capsule polysaccharide or conjugated to a protein or the antigen attached. This protein plays a vital role in enhancing the immunogenic property of the polysaccharide which helps to protect the body from microorganisms.

Thanks for reading this article; you can also get individual chapter wise section or region wise report version like North America, Europe or Southeast Asia.

[sudheervanguri]

Bharat Biotech Fresher Jobs for Lifesciences Candidates: Ignite Your Career in Bioprocessing and Formulation Introduction Embark on an exciting journey with Bharat Biotech International Limited, a pioneer in the field of biopharmaceuticals. This blog post unveils exclusive opportunities for freshers in the Production Department, focusing on Bio Process and Formulation & Filling. Dive into the details about the company, available job positions, and how to apply for these promising roles. About the Company Bharat Biotech International Limited Bharat Biotech International Limited stands at the forefront of the biopharmaceutical industry, contributing to global healthcare through innovative vaccines and biotherapeutics. Committed to research, development, and manufacturing, Bharat Biotech has earned a stellar reputation for its contributions to public health. Company Vacancies List Position Title: Production Trainee Company Name: Bharat Biotech International Limited Salary: As Per Company Norms Company Address: Hyderabad, India Role: Production Trainee Industry Type: Biopharmaceuticals Department: Production (Bio Process / Formulation & Filling) Employment Type: Full-time Role Category: Production Education UG: B.Sc (Chemistry/Biotechnology) / B.Pharmacy / B.Tech Biotech / Diploma/ITI PG: M.Sc (Chemistry/Biochemistry/Biotechnology) [caption id="attachment_57664" align="aligncenter" width="930"] Bharat Biotech Hiring Production Executives in Hyderabad - Apply Now[/caption] Key Skills Bioprocessing, Formulation & Filling, Production, Biochemistry, Biotechnology How to Apply Interested candidates are invited to share their updated CVs with "careers@bharatbiotech.com". Please mention "Production Trainee" in the subject line.